Literature DB >> 10759029

Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides.

M Blüthner1, M Mahler, D B Müller, H Dünzl, F A Bautz.   

Abstract

The polymyositis-scleroderma overlap syndrome (PM/Scl) autoantigen is a nucleolar multiprotein particle, presumably participating in the maturation of 5.8S rRNAs. The major target antigens of this particle are two polypeptides with apparent molecular masses of 100 and 75 kDa. In this study we identified the major linear epitopes along the PM/Scl-100 protein sequence by probing overlapping oligopeptides with anti-PM/Scl autoantisera. A major epitope region was identified between amino acids 231 and 245 of the PM/Scl-100 polypeptide. Mutational analysis of the corresponding peptide LDVPPALADFIHQQR by glycine-walk followed by immunodetection of the resulting peptides indicated that amino acids 234, 237, 240, and 241 of the PM/Scl-100 autoantigen are essential for binding of the corresponding antibodies. These results allow us to propose a local alpha-helical secondary structure for the PM/Scl-100 major epitope region. A homology search with the peptide LDVPPALADFIHQQR against the Swiss-Model three-dimensional database reveals some topological homology of the PM/Scl-100 major epitope region with the heterochromatin modifier protein p25beta, a known autoantigen recognized by antibodies from a subset of scleroderma patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759029     DOI: 10.1007/s001099900072

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  9 in total

1.  Activities of human RRP6 and structure of the human RRP6 catalytic domain.

Authors:  Kurt Januszyk; Quansheng Liu; Christopher D Lima
Journal:  RNA       Date:  2011-06-24       Impact factor: 4.942

2.  Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.

Authors:  K Kessenbrock; M J Fritzler; M Groves; P Eissfeller; C A von Mühlen; P Höpfl; M Mahler
Journal:  J Mol Med (Berl)       Date:  2007-08-01       Impact factor: 4.599

3.  CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.

Authors:  Xiao-Feng Yang; Catherine J Wu; Linyun Chen; Edwin P Alyea; Christine Canning; Philip Kantoff; Robert J Soiffer; Glenn Dranoff; Jerome Ritz
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

Review 4.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

5.  Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.

Authors:  Michael Mahler; Reinout Raijmakers; Cornelia Dähnrich; Martin Blüthner; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2005-04-01       Impact factor: 5.156

Review 6.  The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.

Authors:  R Brouwer; G J Pruijn; W J van Venrooij
Journal:  Arthritis Res       Date:  2000-12-20

Review 7.  Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hajime Yoshifuji
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-04-03

8.  Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.

Authors:  Katharina Hanke; Claudia S Brückner; Cornelia Dähnrich; Dörte Huscher; Lars Komorowski; Wolfgang Meyer; Anthonia Janssen; Marina Backhaus; Mike Becker; Angela Kill; Karl Egerer; Gerd R Burmester; Falk Hiepe; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

9.  Three unique Sendai virus antigenic peptides screened from nucleocapsid protein by overlapping peptide array.

Authors:  Zhiguang Xiang; Wei Tong; Yuhan Li; Chuan Qin; Qiang Wei
Journal:  J Virol Methods       Date:  2013-06-28       Impact factor: 2.014

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.